241 related articles for article (PubMed ID: 36246617)
21. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
22. Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver.
Hewitt DB; Rahnemai-Azar AA; Pawlik TM
Expert Opin Investig Drugs; 2021 Aug; 30(8):827-835. PubMed ID: 34102935
[No Abstract] [Full Text] [Related]
23. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
24. Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.
Shen S; Chen L; Liu J; Yang L; Zhang M; Wang L; Zhang R; Uemura Y; Wu Q; Yu X; Liu T
Cancer Biol Med; 2020 Aug; 17(3):555-568. PubMed ID: 32944390
[TBL] [Abstract][Full Text] [Related]
25. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.
Zhu Y; Qin LX
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):420-429. PubMed ID: 35977874
[TBL] [Abstract][Full Text] [Related]
26. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
27. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
Guardascione M; Toffoli G
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
[TBL] [Abstract][Full Text] [Related]
28. Current status and advances of immunotherapy in nasopharyngeal carcinoma.
Xu JY; Wei XL; Wang YQ; Wang FH
Ther Adv Med Oncol; 2022; 14():17588359221096214. PubMed ID: 35547095
[TBL] [Abstract][Full Text] [Related]
29. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
30. Advances in clinical immunotherapy for gastric cancer.
Li K; Zhang A; Li X; Zhang H; Zhao L
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188615. PubMed ID: 34403771
[TBL] [Abstract][Full Text] [Related]
31. Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations.
Zhang Q; Chen Y; Bai X; Liang T
Front Oncol; 2020; 10():590058. PubMed ID: 33178615
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors.
Jiang S; Geng S; Luo X; Zhang C; Yu Y; Cheng M; Zhang S; Shi N; Dong M
Front Immunol; 2022; 13():995785. PubMed ID: 36189266
[TBL] [Abstract][Full Text] [Related]
33. Cancer Immunoprevention: Challenges and Potential Opportunities for Use of Immune Checkpoint Inhibitors.
Mohammed A; Shoemaker RH; Sei S
Cancer Prev Res (Phila); 2020 Nov; 13(11):897-900. PubMed ID: 32948608
[TBL] [Abstract][Full Text] [Related]
34. Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma.
Cui TM; Liu Y; Wang JB; Liu LX
Onco Targets Ther; 2020; 13():11725-11740. PubMed ID: 33235462
[TBL] [Abstract][Full Text] [Related]
35. Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma.
Tian BW; Han CL; Dong ZR; Tan SY; Wang DX; Li T
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011030
[TBL] [Abstract][Full Text] [Related]
36. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
37. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
Wong KM; King GG; Harris WP
Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
[TBL] [Abstract][Full Text] [Related]
38. Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma.
Wang T; Zhang Q; Wang N; Liu Z; Zhang B; Zhao Y
Curr Med Chem; 2021; 28(16):3107-3146. PubMed ID: 33050856
[TBL] [Abstract][Full Text] [Related]
39. [Immunotherapy clinical application and research prospects for liver cancer].
Xia F; Chen XP
Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):615-617. PubMed ID: 34371529
[TBL] [Abstract][Full Text] [Related]
40. T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy.
Bian J; Lin J; Long J; Yang X; Yang X; Lu X; Sang X; Zhao H
Am J Cancer Res; 2020; 10(12):4585-4606. PubMed ID: 33415021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
